Partners

Biomay's R&D in innovative allergy therapeutics forms the hub of an extensive collaboration network in Austria. This network comprises two major universities, and well over 50 experienced scientists. 

Members of Biomay’s Allergy Network

Rudolf Valenta, MD
Professor for Allergology at the Medical University of Vienna,
Department of Pathophysiology / Division of Immunopathology, Research area: Immunopathology and vaccine development. He is the major force behing Biomay’s development product platform.

Fatima Ferreira, PhD
Associate Professor at the University of Salzburg,
Department of Molecular Biology / Division of Allergy and Immunology,
Research area: Development of recombinant allergens for immunotherapy and diagnosis

Barbara Bohle, PhD
Professor at the Medical University of Vienna,
Department of Pathophysiology / Division of Immunopathology,  Research area: Allergen-specific T cell responses and adjuvant development

Margarete Focke-Tejkl, PhD
Associate Professor at the Medical University of Vienna
Department of Pathophysiology / Division of Immunopathology, Research area: B-cell epitope-based vaccine development 

Josef Thalhamer, PhD
Associate Professor at the University of Salzburg,
Department of Molecular Biology / Division of Allergy and Immunology,  Research area: Genetic immunization, protective and therapeutic RNA / DNA vaccines

Susanne Vrtala, PhD
Associate Professor at the Medical University of Vienna,
Department of Pathophysiology / Division of Immunopathology,  Research area: Diagnostic allergen micro-arrays 

To support the clinical development of its allergy vaccines, Biomay has assembled an Advisory Board of Key International Opinion Leaders in the field of allergy immunotherapy 

 

 

Biomay's Clinical Advisory Board

Biomay is supported by a Clinical Advisory Board (CAB) of world leading allergy specialists. These distinguished and internationally acclaimed scientists agreed to accept the appointment to the CAB:

- Marianne van Hage (Prof. at Karolinska Institute, Stockholm, Sweden)   

- Peter S. Creticos (Prof. at Johns Hopkins University, Baltimore, Maryland, USA)  
  
- Stephen R. Durham (Prof. at Imperial College, London, UK)

- Marek Jutel (Prof. at Wroclaw Medical University, Wroclaw, Poland)

- Hans Ulrich Wahn (Prof. at Charité, Berlin, Germany)

The CAB’s charter is to support the clinical development process of the company’s lead product BM32 through expert advice. The members have committed themselves to support Biomay conducting its clinical development program according to the highest medical standards using cutting edge scientific concepts.